ArticleVaccine: X2023
High-dose influenza vaccine in older adults by age and seasonal characteristics: Systematic review and meta-analysis update.
Article in Vaccine: X, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 56 citations in OpenAlex.
- High-Dose vs Standard-Dose Influenza Vaccine and Cardiovascular Outcomes in Older Adults: A Prespecified Secondary Analysis of the DANFLU-2 Randomized Clinical Trial.JAMA cardiology · 2025Trial
- High-Dose vs. Standard-Dose Influenza Vaccine in Older Patients With Hypertension: A Post Hoc Analysis of DANFLU-1.Journal of clinical hypertension (Greenwich, Conn.) · 2025Trial
- Boosting effect of high-dose influenza vaccination on innate immunity among elderly.JCI insight · 2025Trial
- Evaluating the cost-effectiveness of adjuvanted influenza vaccine in the older adult population in the Netherlands.Human vaccines & immunotherapeutics · 2026Article
- Travel vaccination in senior travelers: current evidence, challenges, and prevention.Tropical diseases, travel medicine and vaccines · 2026Review
- Cost-effectiveness analysis of influenza vaccination with high-dose vaccine versus standard-dose quadrivalent vaccine in older adults in Spain.The European journal of health economics : HEPAC : health economics in prevention and care · 2026Article
- Article
- Alternative approaches to phase III clinical trials for vaccine efficacy and licensure: the role of real-world evidence - a meeting report.Biologicals : journal of the International Association of Biological Standardization · 2026Article
- Influenza Vaccines for Persons Who Are Immunocompromised: A Scoping Review of the Literature.Open forum infectious diseases · 2026Article
- Evaluation of Safety and Immunogenicity of High-Dose Quadrivalent Seasonal Influenza Split Vaccine: A Preclinical Study.Vaccines · 2026Article
- High-dose influenza vaccine augments serological and cellular immunity of older people with HIV.JCI insight · 2026Article
- Correspondence About the Paper "Effectiveness of High-Dose Influenza Vaccine Against Hospitalisations in Older Adults (FLUNITY-HD): An Individual Level Pooled Analysis" by Niklas Dyrby Johansen et al., https://doi.org/10.1016/S0140-6736(25)01742-8.Influenza and other respiratory viruses · 2026Article
- Effects of Respiratory Vaccines in Older Adults with Cardiovascular Diseases: A Scoping Review.Vaccines · 2026Review
- Review
- Age-dependent immune landscapes affect influenza vaccine effectiveness and guide precision strategies.Frontiers in immunology · 2026Review
- State-of-the-art of the high dose influenza vaccine in Spain.Frontiers in immunology · 2026Review
- Cost-Effectiveness Analysis of the High-Dose Trivalent Influenza Vaccine in the Elderly Population in Italy.ClinicoEconomics and outcomes research : CEOR · 2026Article
- Immunosenescence and susceptibility to respiratory viruses: a state-of-the-art review.European respiratory review : an official journal of the European Respiratory Society · 2026Review
- Article
- Influenza Vaccination Appropriateness: Insights from the Local Health Unit of Catania During the 2023/2024 and 2024/2025 Seasons.Vaccines · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This updated systematic review and
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.